Anifrolumab for refractory lupus erythematosus panniculitis in systemic lupus erythematosus

Rheumatology (Oxford). 2024 Mar 1;63(3):e115-e117. doi: 10.1093/rheumatology/kead553.

Authors

Keisuke Maeshima¹, Tasuku Abe², Chiharu Imada², Takashi Ozaki², Hirotaka Shibata²

Affiliations

¹ Department of Rheumatology, Nishida Hospital, Oita, Japan.
² Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan.

PMID: 37819922
DOI: 10.1093/rheumatology/kead553

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Lupus Erythematosus, Systemic* / complications
Lupus Erythematosus, Systemic* / drug therapy
Panniculitis, Lupus Erythematosus* / drug therapy

Substances

anifrolumab
Antibodies, Monoclonal, Humanized